Sunitinib alone substantially extended overall survival (median survival: 15 vs 24 d; p < 0.05) of B16F10 tumor‐bearing mice, and combined with anti‐CTLA‐4 enhanced survival benefit (median survival time: 15 vs 57 d; p < 0.05; Figure 6I). Here, CTLA4 is linked to neoplasm.